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DRUG  REVIEW
Introduction
Nausea and vomiting are common and distressing side
effects of the chemotherapy. However, the drugs used
for chemotherapy vary in the extent to which they cause
nausea and vomiting. Highly emetogenic drugs like
cisplatin result in severe nausea in most patients as
compared to moderately emetogenic ones. Agents
commonly used for the treatment of chemotherapy
induced vomiting include dopamine antagonists, 5HT3
antagonist and corticosteroids (1). Search for the novel
agents has led to the development of Aprepitant, which
is a neurokinin 1 receptor blocker.
Chemistry and Mechanism of Action
Aprepitant is chemically described as 5-[[(2R,3S)-2-
[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-
fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-
1,2,4-triazol-3-one.Its empirical formula is
C23H21F7N4O3, and its structural formula is:
                
Aprepitant is a white to off-white crystalline solid
(molecular weight: 534.43). It is practically insoluble in
water, sparingly soluble in ethanol and isopropyl acetate
and slightly soluble in acetonitrile (2).
Aprepitant is a selective Neurokinin-1 receptor
antagonist which is substance P preferring G-protein
coupled receptor located in the central nervous system
and peripheral nervous system. It has little or no affinity
for serotonin, dopamine or corticosteroids receptors.
Substance P is a neuropeptide which sends and receives
impulses and messages from the brain. It is found in high
concentration in the vomiting center of the brain and when
activated it results in vomiting reflux. Aprepitant has been
shown to inhibit both acute and delayed emesis induced
by cytotoxic chemotherapeutic such as cisplatin by
blocking substance P. In addition to this, it also plays a
key part in transmission of pain impulses from the
peripheral receptors to the CNS and is involved in various
behavioural, neurochemical and cardiovascular responses
to stress (3).
Pharmacokinetics
Aprepitant is given orally and its oral bioavailability is
approximately 60 to 65%. The recommended dose of
aprepitant is 125 mg orally one hour prior to chemotherapy
treatment (Day 1) and 80 mg once daily in the morning
on Days 2 and 3. Following these doses, the Cmax occurs
in approximately 4hrs and reaches about 1.5μg/ml. The
drug is slowly absorbed, highly bound to plasma protein
(95%) and mean volume of distribution is approximately
70L. It crosses the blood brain barrier. The half life of
aprepitant is 9-13hrs. Data indicate that aprepitant is
extensively metabolized by CYP3A4 and to a lesser
degree, by CYP1A2 and CYP2C19. Plasma
concentrations of aprepitant may be reduced by
CYPP3A4 inducers like carbamazepine, phenytoin and
rifampicin and increased by CYP3A4 inhibitors like
clarithromycin, ketoconazole, nelfinavir and ritonavir. It
is excreted in both urine & faeces (2).
Clinical Use
Addition of aprepitant to standard regimen of
ondansetron and dexamethasone provides superior
antiemetic protection in patients with cancer, receiving
high dose cisplatin based chemotherapy (4). This better
antiemetic protection of aprepitant when administered in
addition to standard antiemtic therapy (5HT3 antagonist
and dexamethasone) is found to be well maintained over
multiple cycles of highly emetogenic therapy (5). A recent
comparative clinical trial was done to study the
effectiveness of a single day three drug regimen of
dexamethasone, palonosetron and aprepitant for
prevention of acute and delayed nausea and vomiting
caused by moderately emetogenic chemotherapy in breast
cancer patients. It showed complete response (no
vomiting, no rescue medication) in 76% patients for acute
period and 66% for the delayed period (6). The aprepitantJK SCIENCE
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regimen has been shown to reduce the requirement of
rescue medication (11%) when compared with the control
group (20%) for prevention of chemotherapy induced
nausea vomiting (CINV) in Chinese breast cancer
patients (7).Aprepitant use in patients receiving high dose
chemotherapy with hematopoietic stem cell support
resulted in prevention of emesis in majority of patient
and was associated with minimal side effects, most
common being hiccups (33%) and drowsiness (33%) (8).
Aprepitant triple therapy was also found to be well
tolerated in adolescent patients and complete response
rates were greater than control, although not statistically
significant. Pharmacokinetics suggested that adult dosing
regimen is appropriate for adolescent patient (9).
Various trials have been carried out to study the other
recognized uses of aprepitant apart from its use in CINV.
Aprepitant has been successfully used for four months
in a patient of refractory diabetic gastroparesis and was
found to improve the patient's quality of life and overall
glycemic control (10). As substance P is a key mediator
in pruritis, it has been suggested that aprepitant causes
potential reduction in substance P induced pruritis (11).
It is also used for postoperative nausea and vomiting.
The recommended oral dosage is 40 mg within 3 hours
prior to induction of anesthesia.Aprepitant has not been
studied in pregnant women.
Adverse Effects
Assessing adverse effects in patients who are given
multiple drugs for their cancers can be difficult. Adverse
events associated with regimens containing aprepitant
include weakness, fatigue, feeling listless, constipation,
diarrhea, anorexia, hiccups, stomach upset, pain and rarely
dizziness and tinnitus (2). A case of ifosfamide induced
neurotoxicity after the addition of aprepitant to an
antiemetic regimen has been reported (12).
Drug Interactions
Aprepitant reduces plasma concentrations of CYP2C9
substrates like phenytoin and warfarin and increases the
plasma levels of CYP3A4 substrates like alprazolam,
dexamethasone, etoposide, ifosamide, vinblastine and
vincristine (2). Hence, the dose of dexamethasone should
be reduced to approximately 50% and the intravenous
and oral dose of methylprednisolone to 25% and 50%,
respectively, when administering along with aprepitant.
Conclusion
Although the efficacy of aprepitant as an aniemetic in
chemotherapy has been proven, questions remain about
its role in practice and its effectiveness in subsequent
cycles of chemotherapy. Although the results of clinical
trial look promising, more studies are warranted.
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